Newberry EP (Elizabeth P Newberry) et al. [170] further used CRISPR-Cas9 to construct two independent liver-specific TM6SF2 knockout (TM6SF2-LKO) mice and gave them a high-fat diet and found that Tm6LKO mice showed steatosis and decreased VLDL-TG secretion because TM6SF2 deficiency impairs the dynamic remodeling of newborn ApoB in VLDL assembly. The gene discussed is TM6SF2; the disease is steatosis.